DSL Acquires Oxford Bio-Innovation

(OBI, Oxford, UK). Terms were not disclosed.

OBI makes and markets diagnostic and research products and has a clinical testing service. Its products include kits and reagents for inhibin A, inhibin B, and activin, all of which play a role in male infertility, assessment of ovarian reserve, prediction of in vitro fertilization (IVF) outcomes, and differential diagnosis of ovarian cancer. The tests are used by clinical and research laboratories worldwide.

DSL develops and manufactures products for global clinical, research, academic, and veterinary markets and currently offers more than 190 immunoassay products. These include tests for fertility and reproduction, thyroid function, growth factors, and bone and mineral metabolism.

"The acquisition of OBI positions DSL as the exclusive global provider of diagnostic tests for the measurement of inhibins and activins,” said Gopal V. Savjani, CEO of DSL.
"DSL's strength in the field of reproductive endocrinology combined with OBI's focus and experience in the area of inhibins and activins will enable us to accelerate the development of additional products and clinical applications in this field.”




Related Links:
DSL